ValuEngine upgraded shares of Cytosorbents (NASDAQ:CTSO) from a sell rating to a hold rating in a research note released on Tuesday, January 9th.
Several other analysts have also recently weighed in on the company. Maxim Group set a $12.00 price target on Cytosorbents and gave the company a buy rating in a report on Monday, January 8th. B. Riley set a $11.00 price target on Cytosorbents and gave the company a buy rating in a report on Friday, December 22nd. Finally, HC Wainwright reaffirmed a buy rating and issued a $13.00 price target on shares of Cytosorbents in a report on Tuesday, November 21st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Cytosorbents has an average rating of Buy and a consensus price target of $10.60.
Cytosorbents (NASDAQ CTSO) opened at $7.80 on Tuesday. The firm has a market capitalization of $223.79, a price-to-earnings ratio of -24.38 and a beta of -0.54. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36. Cytosorbents has a 12 month low of $3.30 and a 12 month high of $7.85.
In other news, CFO Kathleen P. Bloch sold 32,400 shares of Cytosorbents stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $7.30, for a total value of $236,520.00. Following the sale, the chief financial officer now directly owns 248,638 shares in the company, valued at approximately $1,815,057.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Vincent Capponi sold 4,000 shares of Cytosorbents stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $7.00, for a total value of $28,000.00. Following the completion of the sale, the chief operating officer now owns 271,062 shares in the company, valued at $1,897,434. The disclosure for this sale can be found here. 5.60% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of CTSO. Fortaleza Asset Management Inc. grew its position in shares of Cytosorbents by 81.6% in the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after buying an additional 10,500 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Cytosorbents by 145.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after buying an additional 22,500 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC bought a new stake in shares of Cytosorbents in the 3rd quarter worth approximately $365,000. Hedge funds and other institutional investors own 8.65% of the company’s stock.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.